These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16835505)

  • 1. Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer.
    Maucort-Boulch D; Roy P
    Eur J Cancer Prev; 2006 Aug; 15(4):347-52. PubMed ID: 16835505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
    Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
    J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
    Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N
    J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
    Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
    Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.
    Green LE; Dinh TA; Hinds DA; Walser BL; Allman R
    Appl Health Econ Health Policy; 2014 Apr; 12(2):203-17. PubMed ID: 24595521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
    Kennecke HF; Olivotto IA; Speers C; Norris B; Chia SK; Bryce C; Gelmon KA
    Ann Oncol; 2007 Jan; 18(1):45-51. PubMed ID: 17030545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
    Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
    J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial.
    Wickerham DL
    Recent Results Cancer Res; 2003; 163():87-95; discussion 264-6. PubMed ID: 12903845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
    Mignotte H; Lasset C; Bonadona V; Lesur A; Luporsi E; Rodier JF; Cutuli B; Lasry S; Mauriac L; Granon C; Kerr C; Giard S; Hill C; de Lafontan B; de Gislain C; D'Anjou J; Fondrinier E; Lefeuvre C; Parache RM; Chauvin F
    Int J Cancer; 1998 May; 76(3):325-30. PubMed ID: 9579567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model.
    Col NF; Goldberg RJ; Orr RK; Erban JK; Fortin JM; Chlebowski RT
    Med Decis Making; 2002; 22(5):386-93. PubMed ID: 12365480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.
    Tang S; Zhang Q; Tang X; Chen D; Zhang F; Liu J; Wei W; Liu D
    J Int Med Res; 2019 Feb; 47(2):641-652. PubMed ID: 30354917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.